VolitionRX Limited

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited's second quarter 2023 earnings conference call. During today's presentation, all parties will be in listen-only mode. Following the presentation, the conference call will be open for questions. If you have questions, please press the star key followed by the number one on your touchstone phone. If you'd like to withdraw your question, please press the star key followed by the number two. If you're using speaker equipment, please lift the handset before making your selections. This conference is being recorded today, August 15th, 2023. I'd now like to turn the call over to Scott Powell, Executive Vice President of Investor Relations.

Please go ahead. Thank you and welcome everyone to today's earnings conference call for VolitionRx Limited. This call will cover Volition's financial and operating results for the second quarter of 2023 and along with a discussion of our recent activities and key upcoming milestones. Following our prepared remarks, we will open the conference call to a question and answer session. Also on our call today are Mr. Cameron Reynolds, President and Group Chief Executive Officer, Mr. Tarek Hughes, Group Chief Financial Officer, and Dr. Tom Butera, Chief Executive Officer of our Volition Veterinary Subsidiary. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views, concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may vary significantly based upon a number of factors that may cause the actual results or events to be materially different from future results, performance, or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward-looking statements made during the course of this conference call. I would now like to turn the call over to our president, and Group Chief Executive Officer, Mr. Cameron Reynolds.

Cameron? Thanks, Scott, and thank you, everyone, for joining Volition's second quarter 2023 earnings call today. I especially appreciate it, given this is the busy earnings call season. We will commence the call with a financial report from our Group Chief Financial Officer, Terry Hughes, before moving on to Dr. Tom Butera, Chief Executive of Volition Veterinary, for an update on the rollout of NewQVet via our global supply and licensing agreements. Finally, I will provide an update on the great progress the team have been making with regards to our product pillars, in particular, NewQNets. Without further ado, I'll hand you across to Tereg for the financial report.